Hepatitis B reverse seroconversion despite entecavir prophylaxis in a myeloma patient on multiple novel agents: a case report and review of the literature-Reference-Cited by-同舟云学术

Hepatitis B reverse seroconversion despite entecavir prophylaxis in a myeloma patient on multiple novel agents: a case report and review of the literature

Published:2020-12-04 Issue:5 Volume:62 Page:1271-1274
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Reynolds Gemma¹,Stewart Tamasine²,Harrison Simon J.²³,Spencer Andrew⁴,Teh Benjamin W.¹³⁵^ORCID

Affiliation:

1. Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia

2. Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia

3. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia

4. Department of Malignant Haematology and Stem Cell Transplantation, Alfred Health, Melbourne, Australia

5. National Centre for Infections in Cancer, Melbourne, Australia

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1855343

Reference16 articles.

1. Reactivation of Hepatitis B Virus in Patients with Multiple Myeloma

2. Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations

3. Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents’ era

4. Incidence and risk factors of hepatitis B virus reactivation in patients with multiple myeloma in an era with novel agents: a nationwide retrospective study in Japan

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antineoplastics;Reactions Weekly;2021-07